Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

6.730 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 101
Open 6.730
Bid (Size) 6.500 (6)
Ask (Size) 6.910 (9)
Prev. Close 6.730
Today's Range 6.730 - 6.730
52wk Range 4.710 - 10.24
Shares Outstanding 128,395,927
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire

Performance

YTD
-23.00%
-23.00%
1 Month
+18.49%
+18.49%
3 Month
+27.22%
+27.22%
6 Month
+11.79%
+11.79%
1 Year
-26.29%
-26.29%

More News

Read More
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia to Participate in Upcoming Investor Healthcare Conferences
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces 2024 Annual General Meeting Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Provides Update on Proxy Statement
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
AUPH Stock Earnings: Aurinia Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
From Aurinia Pharmaceuticals Inc.
Via Business Wire
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
From Aurinia Pharmaceuticals Inc.
Via Business Wire
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia to Participate in Upcoming Investor Healthcare Conferences
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Aurinia Pharmaceuticals Finds No Buyer After Strategic Business Review, Launches Stock Buyback
Via Benzinga
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.